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Objectives. This study assessed the safety and efficacy of 
carvedilol in patients with heart failure caused by idiopathic or 
ischemic cardiomyopathy. 
Background. Carvedilol is a mildly betas-selective beta- 
adrenergic blocking agent with vasodilator properties. Beta- 
blockade may be beneficial in patients with heart failure, but the 
effects of carvedilol are not known. 
Methods. Sixty patients with heart failure (New York Heart 
Association functional classes II to IV) and left ventricular 
ejection fraction <0.35 were enrolled in the study. All patients 
tolerated challenge with carvedilol, 3.125 mg twice a day, and were 
randomized to receive carvedilol (n = 36) versus placebo (n = 24). 
Study medication was titrated over 1 month from 6.25 to 25 mg 
twice a day (<75 kg) or 50 mg twice a day (>75 kg) and continued 
for 3 months. One placebo-treated and two carvedilol-treated 
patients did not complete the study. 
Results. Carvedilol therapy resulted in a significant reduction 
in heart rate and mean pulmonary artery and pulmonary capillary 
wedge pressures and a significant increase in stroke volume and 
left ventricular stroke work. Left ventricular ejection fraction 
increased 52% in the carvedilol group (from 0.21 to 0.32, p < 
0.0001 vs. placebo group). Carvedilol-treated patients also re- 
ported a significant lessening of heart failure symptoms (p < 0.05 
vs. placebo group). Submaximal exercise duration tended to 
increase with carvedilol therapy (from 688 - 31 s to 871 -+ 32 s), 
but this change was not significantly different from that with 
placebo therapy by between-group analysis. Peak oxygen con- 
sumption during maximal exercise did not change. 
Conclusions. Long-term carvedilol therapy improves rest car- 
diac function and lessens ymptoms in patients with heart failure. 
(J Am Coil Cardiol 1995;25:1225-31) 
Adrenergic activation in heart failure appears to have adverse 
effects on myocardial function (1,2) and signal transduction 
(3,4). This finding has led to renewed interest in the therapeu- 
tic use of beta-adrenergic blocking agents in patients with heart 
failure. Early reports (5,6) suggested that beta-blockade may 
improve hemodynamic function in patients with heart failure 
caused by idiopathic dilated cardiomyopathy. Subsequent re- 
ports (7-17) have mostly supported this finding, but available 
data from long-term placebo-controlled trials are limited. We 
recently reported (12) that long-term therapy with bucindolol, 
a nonselective beta-blocker with weak vasodilator activity, 
improves rest cardiac function and lessens ymptoms of heart 
failure in patients with idiopathic dilated cardiomyopathy. The 
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improvement in left ventricular dysfunction with bucindolol 
appears to be dose dependent (16). Few trials have included 
patients with heart failure caused by ischemic ardiomyopathy, 
but the initial experience suggested that these patients may 
also benefit from beta-blockade (13,15-17). 
The effect of beta-blockade on exercise tolerance in pa- 
tients with heart failure remains unclear. This uncertainty is
due in part to the finding that maximal exercise tolerance is 
heart rate-dependent, and the use of beta-adrenergic blockers 
may significantly lower maximal exercise heart rate (12,15,16). 
Thus, standard maximal exercise protocols used in previous 
trials may not adequately assess clinically relevant changes in 
exercise tolerance in patients with heart failure treated with 
beta-blockade. The ideal method for evaluating changes in 
exercise tolerance during beta-blocker therapy would not be 
dependent on maximal heart rate but would reflect improve- 
ment in submaximal exercise tolerance. 
Carvedilol is a potent, mildly betal-selective b ta-blocking 
agent with vasodilator properties related to alphal-receptor 
blockade (18-21). These complementary pharmacologic ac- 
tions occur within the same dose range. Although the beta- 
blocking action of the drug may provide therapeutic benefit as 
described earlier, the vasodilating properties may attenuate 
the worsening of hemodynamic function that often accompa- 
nies initiation of beta-blockade in patients with heart failure. A 
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small uncontrolled trial (22) of carvedilol suggested that this 
agent was well tolerated and improved left ventricular function 
and exercise tolerance. We report the results of a controlled 
trial of carvedilol in patients with heart failure. 
Methods  
Study objectives. The primary objective of the present 
study was to assess the safety and tolerability of carvedilol in 
patients with chronic heart failure caused by either ischemic or 
idiopathic dilated cardiomyopathy. Secondary objectives were 
to assess the effects of long-term carvedilol therapy on left 
ventricular function, symptoms of heart failure and exercise 
tolerance. 
Study design. This study was a 4-month prospective, ran- 
domized, double-blind, placebo-controlled trial. The trial con- 
sisted of four phases: a 2- to 4-week baseline period, a 1-week 
challenge period, an up-titration period and a double-blind 
treatment phase. Patients were randomized to receive carve- 
dilol or placebo n a 3:2 basis with a block size of 5. End points 
of the study included completion of the study, significantly 
worsening heart failure not improved with adjustments in
conventional medications, cardiac transplantation r death. 
Patient eligibility. Patients 18 to 80 years old were eligible 
for study entry if they had symptomatic but stable heart failure 
(New York Heart Association functional class II or III) caused 
by ischemic or idiopathic dilated cardiomyopathy and a radio- 
nuclide left ventricular ejection fraction <0.35. Patients were 
excluded if they had valvular heart disease as the etiology of 
left ventricular dysfunction, active myocarditis, active angina, a 
documented history of sustained (> 15 s) ventricular tachycar- 
dia or symptomatic nonsustained ventricular tachycardia not 
adequately controlled by antiarrhythmic drugs or second- or 
third-degree atrioventricular block unless equipped with a 
permanent pacemaker. Patients were also excluded if their 
exercise duration was <3 or >30 rain on the maximal exercise 
protocol. Patients with symptomatic peripheral vascular dis- 
ease; chronic obstructive lung disease; bronchial asthma; insulin- 
dependent diabetes mcllitus; long-term alcohol or drug abuse; or 
chronic renal, hepatic, hematologic, neurologic or collagen vas- 
cular disease were excluded. All subjects gave written informed 
consent approved by the Human Subjects Committee of the 
Institutional Review Board of the University of Utah. 
Concomitant medications. Permissible concomitant medi- 
cations included igitalis, diuretic drugs, digoxin, class I anti- 
arrhythmic drugs, angiotensin-converting enzyme inhibitors, 
anticoagulant agents, nitrates (given for heart failure therapy 
but not for angina) and hydralazine. Adjustment of cardiac 
medication doses was not permitted uring the screening or 
baseline phases but was permitted when clinically indicated 
during the remainder of the study. Patients received anticoag- 
ulation when clinically appropriate, generally for left ventric- 
ular ejection fraction <0.25 or atrial fibrillation. Excluded 
medications were other beta-blockers, amiodarone, calcium 
channel blockers, monoamine oxidase inhibitors, tricyclic an- 
tidepressant agents, beta-agonists, reserpine, guanethidine and 
antihypertensive medications. Other noncardiac medications 
were administered when appropriate. 
Study measures. Two graded maximal bicycle ergometeric 
exercise tolerance tests were performed with measurement of 
peak oxygen consumption. The maximal protocol consisted of 
2 rain of free pedaling followed by incremental exercise to 
exhaustion, with work load ramped at either 5 or 10 W/min so 
that the total duration of exercise would be between 8 and 
15 rain. Dyspnea nd fatigue were the required end points to 
terminate xercise. Any alternative reasons for terminating 
exercise xcluded the patient from further participation. Ex- 
pired gas analysis was performed by mass spectrometry (23). 
Peak oxygen consumption was defined as the average oxygen 
consumption during the last minute of maximal exercise. For 
study entry, it was required that the two consecutive values for 
total exercise duration or peak oxygen consumption not vary 
>30%. The values of the two tests were then averaged to 
obtain the baseline maximal exercise values. A submaximal 
bicycle exercise tolerance test was then performed using the 
average maximal peak oxygen consumption from the tests to 
determine the appropriate work level (24). During the sub- 
maximal protocol, the patient exercised at a work load equal to 
66% of the peak oxygen consumption ofthe maximal exercise 
test for 6 rain, after which the work load was increased to 85% 
of the maximal peak oxygen consumption of the maximal 
exercise test. Exercise was then continued to exhaustion. Total 
exercise duration was the end point for the submaximal test. 
Patients meeting the exercise ligibility requirements then 
underwent radionuclide ventriculography at rest and during 
maximal supine bicycle exercise to determine l ft ventricular 
ejection fraction. Echocardiography was performed to deter- 
mine left ventricular diastolic and systolic dimensions using 
standard M-anode measurements. A 24-h Holter recording was 
obtained. Cardiac function was assessed using a questionnaire 
modified from that of Lee et al. (25) with a composite symptom 
score. Scores ranged from 0 or no symptoms to 13 or most 
severe heart failure symptoms. Functional class was assessed 
by two investigators in a blinded manner. 
Routine clinical laboratory testing, including chest radiogra- 
phy, electrocardiography, complete blood count, multichannel 
chemistry panel and urinalysis, was performed uring the 
baseline period and repeated routinely throughout the study 
for safety monitoring. 
On completion of these tests, eligible patients were admit- 
ted to the hospital for hemodynamic measurements by right 
heart catheterization. Patients were studied in the morning 
several hours after an overnight fast. Cardiovascular medica- 
tions with the exception of class I antiarrhythmic agents, were 
withheld before the procedure. Right atrial, pulmonary artery 
and pulmonary capillary wedge pressures were measured. 
Cardiac output was determined by the Fick method. Systemic 
arterial pressures were measured by an arterial line placed in 
either a radial or femoral arterial catheter and heart rate was 
determined by electrocardiographic (ECG) telemetry monitor- 
ing during the procedure. Left ventricular stroke work was 
calculated using the formula: Stroke work -- (Stroke volume 
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index) × (Mean arterial pressure - Mean wedge pressure) × 
0.0136. 
Open-label challenge period. After baseline measure- 
ments, an open-label carvedilol challenge was administered at 
3.125 mg every 12 h for 7 days. 
Up-titration and double-blind treatment phases. Patients 
who successfully completed the open-label challenge were then 
randomized tothe blinded treatment phase in a ratio of 3:2 for 
carvedilol versus placebo treatment, respectively. Study medi- 
cation was initiated at a dose equivalent to 6.25 nag orally every. 
12 h. For each new dose of study medication, vital signs were 
monitored for at least 2 h after the first dose was administered. 
At each weekly clinic visit, patients were evaluated for symp- 
toms and signs of worsening heart failure, hypoperfusion or 
other adverse ffects possibly related to beta-blocker therapy. 
If no adverse ffects were observed, doses of carvedilol versus 
matched placebo were then titrated upward in weekly intervals 
until either a maximal tolerated ose or the maximal allowed 
dose was reached. The maximal allowed dose was 25 mg twice 
a day for patients weighing <75 kg and 50 nag twice a day for 
those weighing >75 kg. The maximal attained close of study 
medication was then continued for a fixed-dose maintenance 
period of 3 months. 
During the final week of the tixed-dose maintenance p riod, 
noninvasive and invasive variables were measured again. 
Carvedilol was administered on the morning of repeat right 
heart catheterization, which was then performed in the late 
morning. 
Statistical analysis. The tolerability and safety of carve- 
dilol were assessed by determining the proportion of patients 
tolerating the open-label challenge and by comparing the 
occurrence of adverse vents in the carvedilol versus placebo 
groups during the double-blind treatment phase. Differences 
between the carvedilol and placebo groups were evaluated by 
repeated-measures analysis of variance for continuous vari- 
ables and by chi-square test for discrete variables. Results are 
expressed as mean value + SEM. Differences were considered 
significant at p < 0.05. 
Results 
Patient characteristics. Sixty subjects were enrolled in the 
study, 43 with idiopathic dilated cardiomyopathy and 17 with 
ischemic ardiomyopathy. All 60 patients tolerated the open- 
label challenge and were randomized toreceive carvedilol (n = 
36) or placebo (n = 24). Of the patients assigned to receive 
carvedilol, 23 had heart failure caused by idiopathic dilated 
cardiomyopathy, and 13 had ischemic ardiomyopathy. In the 
placebo group, 2(1 patients had idiopathic dilated cardiomyop- 
athy, and 4 had ischemic ardiomyopathy. 
Baseline characteristics are shown in Table 1. The treat- 
ment groups did not differ with respect o age, male/female 
ratio, left ventricular ejection fraction, pulmonary capillary 
wedge pressure, cardiac index or peak oxygen consumption. 
There was a trend for more patients with functional class III 
heart failure symptoms in the carvedilol group, but the differ- 
Table I. Clinical Characteristics of 60 Study Patients 
Carvedilol Group Placebo Group 
(n = 36) (n = 24) 
Age (yr) 54 -+ 2 50 -+ 3 
Range 29-73 24-68 
Gender (male/female) 3,4/2 22/2 
NYHA functional class 
11 16 14 
III 20 10 
LVEF 0.20 ± 0.0l 0,19 _+ 0,01 
CI (liters/rain per m 2) 2.2 = 0.1 2.2 _+ 0.1 
PCWP (mm Hg) 17 ± 2 15 ± 2 
Norepinephrine (pg/ml) 558 ± 75* 337 ± 43* 
Concomitant medications 
Diurctic drugs 30 (83%) 19 (79%) 
Digoxin 33 (92%) 17 (71%) 
ACE inhibitors 32 (89%) 24 (100%) 
Vasodilator drugs 3 (8%) 3 (12%) 
Antiarrhylhmic agents 6 (17%) 5 (21%) 
Warfarin 28 (78%) 18 (75%) 
Dose of study drug (mg/day) 80 ± 9 83 + 5 
*p 0.02. Data presented are mean value ± SEM or number (%) of 
patients. ACE angiotensin-converting enzyme; CI - cardiac index; LVEF 
left ventricular ejection fraction; NYHA - New York Heart Association; 
PCWP = pulmonary capillary, wedge pressure. 
ence compared with the placebo group was not significant. 
Plasma venous norepinephrine concentrations were higher in 
the carvedilol group. Concurrent medical therapy did not differ 
significantly between the treatment groups. There were no 
intergroup differences in changes to concomitant medications 
during the maintenance p riod. 
Three patients did not complete the protocol. One patient 
with ischemic ardiomyopathy who was randomized toreceive 
carvedilol withdrew because of significantly worsening heart 
failure during up-titration. A second patient with ischemic 
cardiomyopathy randomized to receive carvedilol died sud- 
denly during up-titration 4 days after reaching a dosage of 
12.5 mg twice a day. In the placebo group, one patient with 
clinically stable isehemic ardiomyopathy in the absence of 
worsening heart failure was electively withdrawn for cardiac 
transplantation when a suitable donor became available. 
One patient with idiopathic dilated cardiomyopathy in the 
carvedilol group had an embolic cerebrovascular ccident 
during the study period, which was not thought to be related to 
the study medication. One patient with idiopathic dilated 
cardiomyopathy in the placebo group sustained anon-Q wave 
myocardial infarction after one dose of carvedilol during the 
open-label challenge. Cardiac atheterization revealed normal 
coronary arteries, and an ergonovine stimulation test failed to 
induce vasospasm; therefore, the event was thought o be 
embolic. This patient completed the open-label challenge 
without further incident. Another patient with idiopathic di- 
lated cardiomyopathy in the placebo group reached the end 
point 4 weeks before completion of the maintenance p riod, 
because of clinical deterioration refractory to adjustments in 
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Table 2. Response  to Carvedi lo l  Therapy:  Noninvasivc Var iables 
Carvedilol Group (n 34) Placebo Group (n - 23) 
Baseline 4 mo Baseline 4 mo p Value 
Symptom score 4.9 + 0.6 2.6 - 0.4 4.2 + 0.1 4.0 -+ 0.7 0.0277 
NYHA functional class 
1 0 4 0 0 
11 16 27 14 16 
111 18 3 l(l 6 0.0170 
IV 0 0 0 1 
LV1DD (mm) 73 :~ 9 70 + 9 79 +_ 14 76 _~ 15 0.7200 
FS (fS) 15 + 0.6 20 +~ 1 17 ± 3 20 ~ 3 0.0037 
Rest LVEF (~)  20 + l 31 + 2 19 + 1 20 -+ 2 0.0001 
Exercise LVEF (%) 21 _+ 1 29 + 2 20 ± 2 21 ± 2 0.0001 
Data presented are mean value + SEM or number of patients. FS - fractional shortcning; LVIDD - left vcntricular 
internal diastolic dimension: other abbreviations a in Fable l. 
conventional medications. This patient completed the end-of- 
study variables, and the data are included in the analysis. 
Noninvasive variables. Results of the noninvasive tests, 
with the exception of exercise and Holter monitoring, are 
shown in Table 2. Patients treated with carvedilol reported a
significant improvement in heart failure symptoms as rated by 
responses to the symptom questionnaire. This self-assessed 
clinical improvement in the carvedilol-treated patients was 
accompanied by an improvement in functional class assigned 
by the clinician. Symptom score and functional class did not 
improve significantly in the placebo group during the study. 
Left ventricular end-diastolic dimension tended to decrease in
both the carvedilol and placebo groups, but the change was not 
significant in either group. Left ventricular end-systolic dimen- 
sion was also reduced in both groups but to a greater degree in 
the carvedilol group. This resulted in a significant improve- 
ment in percent fractional shortening in the carvedilol group. 
In the carvedilol group, rest left ventricular ejection fraction 
increased by 52%; there was no change in the placebo group. 
There was a corresponding increase in exercise left ventricular 
ejection fraction for the carvedilol group, but this change did 
not appear to be independent of the improvement in rest 
ejection fraction. 
Invasive hemodynamic variables. Table 3 presents the 
hemodynamic measurements a  baseline and at the end of the 
4-month trial for both treatment arms. There were no signifi- 
cant differences between the groups at baseline, although the 
pulmonary capillary wedge pressure tended to be higher in the 
carvedilol group. As would be expected, therapy with carve- 
dilol significantly reduced rest heart rate by 23%. No signifi- 
cant changes in systemic arterial or systemic venous pressures 
were observed in either group. A significant decrease in both 
pulmonary artery and pulmonary capillary wedge pressures 
occurred in the carvedilol but not the placebo group. Cardiac 
index did not increase significantly with carvedilol, most likely 
reflecting the drug's effect on rest heart rate. However, both 
stroke volume and left ventricular stroke work index were 
markedly improved with carvedilol therapy compared with 
placebo therapy. 
In Figure 1, stroke volume index is plotted as a function of 
pulmonary artery wedge pressure at baseline and at the end of 
study (4 months) for each treatment group. There was a 
Table  3. Response  to Carvcdi lo l  Therapy:  Hcmodynamic  Var iab les  
Caiwcdilol Group (n - 34) Placebo Group (n 23) 
P 
Baseline 4 mo Baseline 4 mo Value 
HR (beats/rain) 87 + 3 67 + 3 83 ± 3 84 ± 3 0.0001 
SAP (ram Hg) 84 + 2 84 - 2 ,$5 + 1 84 ± 2 0.7182 
RAP (ram Hg) 5 - 1 4 + 1 5 -+ 1 5 - 1 0.7480 
PAP (mm Hg) 2a; + 2 22 + 2 25 -- 3 25 ± 2 0.0205 
PCWP (ram Hg) 17 + 2 12 + I 15 ± 2 15 + I 0.0213 
CI (liters/min per m 2) 22 + 0.1 2.4 + 0.1 2.2 ± 0.1 2.2 ± 0.l 0.4000 
SVI (ml/beats per min) 26 _+ 2 38 ± 2 26 _+ 1 27 + 2 0.0004 
SVR (Wood U) 20 _+ 1 18 + 1 19 ± 1 18 + 1 0.4826 
PVR (Wood U) 2.9 + 0.3 2.1 + 0.2 3,1 + 0.5 2.3 ± 0.3 0.8959 
LVSWI (g.m/m 2) 26 ~ 3 38 ~ 3 29 ± 4 27 + 2 0.0033 
Data presented arc mean value ~ SEM. HR heart rate; LVSWI - left vcntricular stroke work index; PAP = 
pulmonary, arteu, pressure; PVR pulmonau, vascular esistance; RAP right atrial pressure; SAP = mean systemic 
arterial pressure: SVI : stroke volume index: SVR - systemic vascular esistance; other abbreviations a  in Table 1. 
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Figure 1. Relation betwcen pulmonary wedge pressure and strokc 
volume index at baseline and at the end of study for the carvcdilol 
(circles) and placebo (squares) groups. Results are mean value + 
SEM. 
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Figure 2. Percent changes inheart rate (HR), pulmonary artery wedge 
pressure (PAWP), cardiac index (C1), stroke volume index (SVI), left 
ventricular stroke work index (LVSWI) and left ventricular ejection 
fraction (LVEF) in the carvedilol (solid bars) and placebo (hatched 
bars) group. Results are mean value _+ SEM *p < 0.001, ?p < I).02, 
change in carvedilol vs. placebo group. 
significant shift upward and to the left of the stroke volume 
index-pulmonary wedge pressure relation after treatment with 
carvedilol; no significant change in this relation was seen in the 
placebo group. 
Figure 2 illustrates the magnitude of relative changes for 
selected variables in the two groups. The difference in percent 
response to carvedilol relative to placebo, obtained by sub- 
tracting the percent change from baseline in the carvedilol 
group from that in the placebo group, was 52% for left 
ventricular ejection fraction and 66% for left ventricular stroke 
work. 
Exercise tolerance testing. Table 4 presents the maximal 
and submaximal exercise data obtained at baseline and at the 
end of study for both treatment groups. Two patients in the 
earvedilol group were excluded from exercise data analysis, 
one because of inability to exercise after a stroke and the 
second because of an exercise time at baseline >30 rain. 
Despite the lessening of symptoms and improvement in func- 
tional class and left ventricular ejection fraction, maximal 
exercise duration and peak oxygen consumption did not im- 
prove with carvedilol therapy. There was a significant decrease 
in maximal exercise heart rate in the carvedilol group. Thus, 
patients receiving carvedilol achieved a comparable l vel of 
exercise at the end of the study, with a reduced rate-pressure 
product, compared with that at baseline. 
Submaximal exercise duration tended to increase after 4 
months of therapy with carvedilol. However, the magnitude of 
the change was not significantly different from that achieved 
with placebo by between-group analysis. 
Ambulatory ECG monitoring. Analyzable 24-h ambulatory 
Holler monitoring was obtained at both baseline and the end 
of study in 33 patients in the carvedilol group and 21 in the 
placebo group. Mean and maximal heart rates (from 87 _+ 3 to 
69 -+ 2 and from 129 +_ 4 to 103 + 3 beats/rain, respectively) 
were significantly reduced in the carvedilol group but were 
unchanged in the placebo group (p - 0.0005 for mean and 
p = 0.05 for maximal heart rate by analysis of variance). The 
carvedilol group showed atendency for a reduction in the total 
number of premature ventricular complexes per hour (from 
186 _+ 56 to 51 _+ 14 beats/h) and number of runs of ventricular 
tachycardia (from 2.4 _+ 1.1 to 0.1 -+ 0.04 runs/h). However, 
these changes failed to achieve statistical significance by 
between-group analysis. 
Discuss ion  
Carvedilol is a mildly beta j-selective beta-blocking agent 
with direct vasodilator action as a result of alphal-receptor 
blockade (18-21). In the present study we evaluated the effects 
of long-term administration f carvedilol compared with those 
of placebo therapy in patients with symptomatic heart failure 
caused by either idiopathic or ischemic cardiomyopathy. In 
both types of symptomatic cardiomyopathy, beta-blockade 
with carvedilol appears to be safe and well tolerated. 
Effects of carvedilol on cardiac function. Long-term ad- 
ministration of carvedilol in the present study was associated 
with a marked improvement i  left ventricular ejection fraction 
and stroke work. Left ventricular stroke volume index in- 
creased significantly with carvedilol therapy, but because of the 
significant decrease in heart rate, rest cardiac output did not 
change. The upward and leftward shift of the stroke volume 
index-pulmonary wedge pressure relation suggests improve- 
ment in intrinsic vcntricular performance, not merely changes 
in loading conditions. Similar findings have been reported for 
bueindolol and nebivolol using both load-dependent (12) and 
load-independent (left ventricular pressure-volume loops) 
measures of left ventricular function (26,27). 
Effects of carvedilol on symptoms and exercise, Carvedilol 
significantly lessened symptoms of heart failure as assessed by 
the patient using a symptom questionnaire and by the clinician 
according to functional class. Although peak oxygen consump- 
tion during exercise did not change with carvedilol therapy, the 
same peak oxygen consumption was achieved at a significantly 
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Table 4. Response to Carvedilol Therapy: Maximal and Submaximat Exercise Tolerance 
Carvedilol Group (n : 32) Placebo Group (n - 23) 
Baseline 4 mo Baseline 4 mo 
P 
Value 
Rest HR (beats/min) 96 _+ 3 72 _+ 3 97 -+ 3 94 + 4 
Exercise HR (beats/min) 152 + 4 12(I + 5 158 _+ 5 153 + 6 
Exercise SAP (ram Hg) 147 + 4 144 + 4 150 + 6 149 _+ 5 
Rate-pressure product (ram Hg beats/rain) 22,548 _+ 1,037 17,559 +_ 924 24,021 + 1,593 23,283 + 1,669 
Exercise duration, max ETF (s) 614 _+ 35 624 +_ 29 640 -+ 37 660 + 37 
Peak oxygen consumption (ml O2/kg per min) 17.5 _+ 0.8 17.5 + 0.9 17.3 -+ 0.8 17.8 + 0.9 








Data presented arc mean value + SEM. max (submax) ETT = maximal (submaximal) exercise tolerance test; other abbreviations as in Table 3. 
lower rate-pressure product. Failure to increase maximal ex- 
ercise capacity is not unexpected because carvedilol therapy 
significantly lowered maximal exercise heart rate, and the 
exercise capacity of patients with heart failure is dependent on 
maximal exercise heart rate (28). This attenuation of heart rate 
response to exercise has been reported to occur with beta- 
blocker therapy in patients with normal left ventricular func- 
tion (29). However, Engelmeier et al. (11) and the Metoprolol 
in Dilated Cardiomyopathy study investigators (13) observed 
improved maximal exercise capacity in patients with heart 
failure treated with metoprolol, although maximal exercise 
heart rate was not reduced in their patients. Maximal exercise 
heart rate was significantly reduced with bucindolol therapy 
(16) and peak oxygen consumption did not change, similar to 
our findings with carvedilol. Thus, maximal exercise tolerance 
testing may be an inadequate method for measuring improved 
exercise capacity in patients with heart failure treated with 
some, but not all dosages or types of beta-blocking agents. 
In the present study, submaximal exercise duration tended 
to increase with carvedilol therapy. However, submaximal 
exercise duration also tended to increase in the placebo group, 
and the between-group change was not statistically significant. 
Neither maximal exercise time nor peak oxygen consumption 
correlated significantly with the change in left ventricular 
function, in agreement with previous observations (30) on the 
lack of a relation between maximal exercise capacity and 
indexes of rest left ventricular function. Similar results have 
been obtained with bucindolol; submaximal but not maximal 
exercise tended to improve on beta-blockade (16). As noted by 
others (31,32), the level of effort required in a submaximal 
exercise test is probably a better approximation of normal daily 
activity in patients with chronic heart failure. Thus, submaxi- 
real exercise testing as performed in the present study appears 
to be a more appropriate method to assess changes in exercise 
capacity in patients with heart failure treated with beta- 
blockade. 
Conclusions. Long-term treatment with carvedilol in pa- 
tients with heart failure as a result of ischemic or idiopathic 
dilated cardiomyopathy results in a significant improvement in 
rest left ventricular function and lessening of symptoms of 
heart failure. Additional trials with larger numbers of patients 
will be needed to determine whether carvedilol improves 
submaximal exercise. Further studies are also needed to de- 
termine the optimal dosage of carvedilol and the effect of 
carvedilol therapy in patients with functional class IV symp- 
toms and to clarify further the response of patients with 
ischemic cardiomyopathy. Several multicenter trials are cur- 
rently under way to address these issues. 
We cxprcss our appreciation for the invaluable contributions of Patrice Mealey, 
RN, Kirk Volkman, RN and Lisa Reynolds, RN in coordinating the study and 
data collection and similarly thank Linda Grayson for assistance in manuscript 
preparation. 
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